血清AIF-1、Bmi-1、MAP19联合诊断宫颈癌的价值分析  

Diagnostic value of combination of serum AIF-1,Bmi-1,and MAP19 in patients with cervical cancer

作　　者：王汇博 陈慧君[1] 朱敏[2] Wang Huibo;Chen Huijun;Zhu Min(Department of Obstetrics and Gynecology,Wuhan University Central South Hospital,Hubei Province,Wuhan 430071,China;不详)

机构地区：[1]武汉大学中南医院妇产科,武汉430071 [2]武汉大学中南医院检验科,武汉430071

出　　处：《疑难病杂志》2024年第8期971-975,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：国家自然科学基金资助项目(82173909)。

摘　　要：目的探究宫颈癌患者血清中同种异体移植物炎性因子1(AIF-1)、B细胞特异性莫洛尼白血病毒插入位点1(Bmi-1)、甘露聚糖结合凝集素相关蛋白19(MAP19)水平变化及对宫颈癌患者的诊断价值。方法选取2023年1—12月武汉大学中南医院妇产科收治宫颈癌患者180例为观察组,另选取同期健康体检者180例为健康对照组。采用酶联免疫吸附法(ELISA)检测2组研究对象血清AIF-1、Bmi-1、MAP19水平;比较宫颈癌不同分期患者血清中AIF-1、Bmi-1、MAP19水平;绘制受试者工作特征(ROC)曲线分析血清AIF-1、Bmi-1、MAP19水平对宫颈癌的诊断价值。结果与健康对照组比较,观察组患者血清AIF-1、Bmi-1、MAP19水平上升(t=13.054、13.598、10.601,P均<0.001);不同分期宫颈癌患者血清中AIF-1、Bmi-1、MAP19水平随分期升高而升高(F=32.001、8.232、10.602,P均<0.001);宫颈癌患者血清AIF-1、Bmi-1、MAP19高水平在病理低分化、HPV阳性、FIGOⅢ~Ⅳ期和淋巴结转移中比例升高(AIF-1:χ^(2)=41.162、27.607、13.718、23.824,P均<0.001;Bmi-1:χ^(2)=33.563、22.060、22.599、18.451,P均<0.001;MAP19:χ^(2)=49.585、14.913、25.545、13.605,P均<0.001);血清AIF-1、Bmi-1、MAP19水平及三者联合预测宫颈癌病变的AUC分别为0.759、0.726、0.751、0.839,三者联合优于各自单独预测价值(Z=2.499、3.363、2.749,P=0.012、<0.001、0.016)。结论宫颈癌患者血清AIF-1、Bmi-1、MAP19水平显著上升,且随宫颈癌分期升高而升高,三者联合对宫颈癌具有较高的诊断效能。Objective To investigate the expression levels of allograft inflammatory factor-1(AIF-1),B-cell specific moloney leukemia virus insertion site 1(Bmi-1),and mannose-binding lectin associated protein 19(MAP19)in serum,and their combined diagnostic value in cervical cancer patients.Methods A total of 180 cervical cancer patients admitted from January 2023 to December 2023 were regarded as the observation group,and another 180 healthy volunteers who underwent physical examinations during the same period were selected as the control group.Enzyme linked immunosorbent assay(ELISA)was applied to detect the expression levels of AIF-1,Bmi-1,and MAP19 in the serum of two groups.The expression levels of AIF-1,Bmi-1 and MAP19 in different stages of cervical cancer were compared.Spearman was applied to analyze the relationship between the expression levels of AIF-1,Bmi-1,MAP19 in serum with the incidence of cervical cancer.Receiver operating characteristic(ROC)curve was plotted to analyze the diagnostic value of serum AIF-1,Bmi-1,and MAP19 expression levels for cervical cancer.Results Compared with the control group,the expression levels of serum AIF-1,Bmi-1,and MAP19 in the observation group were increased(t=13.054,13.598,10.601,P<0.001);The expression levels of AIF-1,Bmi-1 and MAP19 in serum of patients with cervical cancer increased with the increase of stage(F=32.001,8.232,10.602,P<0.001).the proportion of high expression levels of serum AIF-1,Bmi-1,and MAP19 in cervical cancer patients increased in pathological low differentiation,HPV positivity,FIGO stages Ⅲ-Ⅳ,and lymph node metastasis,while the proportion of low expression levels increased in pathological moderate to high differentiation,HPV negativity,FIGO stagesⅠ-Ⅱ,and no lymph node metastasis(AIF-1:χ^(2)=41.162,27.607,13.718,23.824,P<0.001,Bmi-1:χ^(2)=33.563,22.060,22.599,18.451,P<0.001,MAP19:χ^(2)=49.585,14.913,25.545,13.605,P<0.001);The AUC for predicting cervical cancer lesions by serum AIF-1,Bmi-1,MAP19 expression levels,and their combination were 0.75

关 键 词：宫颈癌 同种异体移植物炎性因子1 B细胞特异性莫洛尼白血病毒插入位点1 甘露聚糖结合凝集素相关蛋白19 诊断 

分 类 号：R737.33[医药卫生—肿瘤] R446.11[医药卫生—临床医学]